Company Overview
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Lewisville, Texas.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.25B (+6.7% YoY); net profit $-1.18B.
- Trailing 12 Months Year-on-year growth — revenue +3.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 9.52% |
| 1 Year: | 3.20% |
Stock Price Performance
| 1 Year: | -28.76% |
| 6 Months: | -12.53% |
| 3 Months: | -25.38% |
| 1 Month: | +15.38% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)60.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 36.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ENOV Enovis Corporation R2KR3KPHARMA | 21.08 | -1.10 | $1.22B | 0.00% | -34.74% | -54.14% | 9.52% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Apr 2020 | Jul 2020 | Oct 2020 | Dec 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Dec 2021 | Apr 2022 | Jul 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Apr 2025 | Jun 2025 | Jul 2025 | Sep 2025 | Oct 2025 | Dec 2025 | Mar 2026 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 533.27M | 560.86M | 524.02M | 574.93M | 683.92M | 908.65M | 846.52M | 888.37M | 816.36M | 620.36M | 805.93M | 828.12M | 311.08M | 356.12M | 359.92M | 399.06M | 375.46M | 395.12M | 383.81M | 408.71M | 406.15M | 428.50M | 417.52M | 516.27M | 525.16M | 505.22M | 558.83M | 558.83M | 564.54M | 564.54M | 548.91M | 548.91M | 575.76M | 589.15M | 589.15M | 582.78M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 226.60M | - | 229.85M | - | 220.00M | - | 226.34M | 223.67M | - | - |
| Gross Profit | 239.83M | 258.06M | 263.90M | 267.68M | 184.58M | 191.93M | 171.27M | 181.59M | 261.01M | 376.06M | 368.14M | 395.84M | 348.21M | 241.09M | 344.12M | 354.69M | 171.28M | 200.59M | 197.88M | 207.92M | 205.90M | 215.91M | 215.82M | 231.75M | 235.06M | 248.36M | 242.97M | 297.90M | 288.88M | 286.46M | 332.23M | 332.23M | 334.70M | 334.70M | 328.91M | 328.91M | 349.42M | 365.49M | 365.49M | 359.25M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 375.14M | - | 350.78M | - | 337.05M | - | 301.17M | 356.25M | - | - |
| Operating Income | 60.22M | 70.12M | 74.77M | - | 62.17M | 45.42M | 35.06M | - | 2.33M | 41.53M | 67.86M | - | 46.84M | -4.92M | 61.93M | - | 61.31M | -10.35M | -16.11M | - | -30.63M | 5.55M | -17.92M | - | -24.97M | -14.49M | -20.49M | -35.01M | -44.22M | -31.74M | -42.91M | -46.77M | -16.08M | -16.80M | -8.14M | -558.49M | 48.25M | 9.24M | 6.53M | 17.41M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.27M | - | 55.19M | - | -483.66M | - | -425.02M | 83.16M | - | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.19M | - | 9.29M | - | 8.83M | - | 7.51M | 9.17M | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -57.35M | - | -25.65M | - | -566.87M | - | -509.55M | 634.00K | - | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.77M | - | 10.80M | - | 4.00M | - | 9.26M | 9.04M | - | - |
| Net Income | 38.54M | 53.39M | 45.86M | - | 24.54M | 38.46M | 31.31M | - | -52.02M | -469.23M | 10.47M | - | - | - | - | - | - | 28.64M | 25.85M | - | 15.07M | 76.86M | -66.61M | - | -23.35M | -9.99M | -2.88M | -72.00M | -18.64M | -31.52M | -55.97M | -55.97M | -36.74M | -36.74M | -571.15M | -571.15M | -520.59M | -8.76M | -8.76M | -1.19M |
| Diluted EPS | 0.31 | 0.43 | 0.37 | 0.11 | 0.20 | 0.31 | 0.26 | 0.39 | -0.39 | -3.45 | 0.08 | -0.12 | 0.03 | -0.06 | 0.10 | 0.24 | 0.40 | 0.56 | 0.49 | -0.04 | 0.28 | 1.41 | -1.23 | -0.71 | -0.43 | -0.18 | -0.05 | -1.32 | -0.34 | -0.58 | -0.98 | -0.98 | -0.64 | -0.64 | -9.99 | -9.99 | -9.10 | -0.15 | -0.15 | -0.02 |
| R&D Expense | - | - | - | - | - | - | - | - | - | 32.60M | 16.30M | - | 18.50M | 14.10M | 16.80M | - | 19.90M | 11.04M | 12.46M | - | 14.84M | 15.66M | 15.60M | - | 18.19M | 18.92M | 19.90M | 23.38M | 23.48M | 20.49M | - | 28.53M | - | 30.70M | - | 29.74M | - | - | 31.53M | 31.69M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 525.02M | 541.99M | 693.39M | 3.91B | 4.21B | 4.62B | 3.43B | 3.19B | 1.94B | 2.19B | 3.33B | 1.12B | 1.43B | 1.56B | 1.71B | 2.11B | 2.25B |
| Gross Profit | 185.79M | 191.41M | 240.10M | 1.15B | 1.31B | 1.48B | 1.07B | 992.38M | 671.58M | 729.38M | 1.40B | 603.64M | 777.67M | 869.38M | 990.78M | 1.18B | 1.35B |
| Operating Income | 39.63M | 34.37M | 25.91M | 140.01M | 406.39M | 409.55M | 265.62M | 236.85M | 135.60M | 151.54M | 203.61M | -66.18M | -62.80M | -71.18M | -65.71M | -775.72M | -1.12B |
| Net Income | 23.80M | 16.21M | 4.55M | -64.40M | 178.63M | 392.10M | 167.74M | 128.11M | 151.09M | 140.20M | -527.65M | 42.62M | 71.66M | -13.29M | -33.26M | -825.49M | -1.18B |
| Diluted EPS | - | 0.37 | 0.10 | -0.92 | 1.54 | 3.02 | 1.34 | 1.04 | 1.22 | 1.16 | -3.89 | 0.93 | 1.40 | -0.25 | -0.61 | -14.93 | -20.75 |
| R&D Expense | 5.93M | 6.21M | 5.71M | - | - | - | - | - | - | - | - | 34.27M | 49.09M | 60.83M | 75.33M | 91.30M | 120.33M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Jan 2011 | Apr 2011 | Jul 2011 | Sep 2011 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Mar 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 1.02B | - | - | - | - | 1.09B | 6.15B | 6.60B | 7.21B | 6.73B | 6.34B | 6.71B | 6.62B | - | 7.39B | 7.35B | 8.52B | 4.27B | 4.51B | 4.72B | 3.83B |
| Total Equity | 181.38M | 216.82M | 216.37M | - | - | - | - | 189.28M | 1.91B | 2.51B | 3.15B | 3.07B | 2.90B | 3.50B | 3.27B | 3.49B | 3.44B | 3.54B | 4.62B | 3.45B | 3.42B | 2.56B | 1.49B |
| Cash & Equivalents | 28.76M | 49.96M | 60.54M | 60.54M | 45.46M | 64.22M | 64.45M | 75.11M | 482.45M | 311.30M | 305.45M | 197.47M | 208.81M | 262.02M | 77.15M | - | 109.63M | 97.07M | 680.25M | 24.30M | 36.19M | 48.17M | 36.39M |
| Long Term Debt | - | - | 72.50M | - | - | - | - | 101.52M | 1.69B | 1.46B | 1.53B | 1.41B | 1.29B | 1.06B | 1.19B | - | 2.28B | 2.20B | 2.08B | 40.00M | 466.16M | 1.31B | 1.26B |
| Total Liabilities | - | - | 805.71M | - | - | - | - | 899.27M | 3.99B | 3.86B | 3.86B | 3.48B | 3.25B | 2.98B | 3.14B | - | 3.90B | 3.76B | 3.85B | 823.45M | 1.09B | 2.15B | 2.34B |
| Current Liabilities | - | - | 191.51M | - | - | - | - | 240.04M | 1.18B | 1.38B | 1.28B | 1.12B | 1.06B | 1.10B | 1.20B | - | 857.31M | 811.66M | 1.02B | 565.20M | 369.61M | 529.00M | 598.47M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 38.70M | 61.97M | 57.15M | 174.02M | 362.17M | 385.76M | 303.81M | 246.97M | 218.77M | 226.37M | 130.95M | 301.94M | 356.10M | -55.86M | 134.99M | 113.50M | 217.29M |
| Investing Cash Flow | -12.46M | -40.41M | -69.97M | -1.94B | -474.97M | -1.03B | -246.96M | -81.99M | 89.88M | -167.85M | -1.63B | -175.08M | -320.48M | -176.39M | -242.47M | -955.47M | -179.37M |
| Financing Cash Flow | -5.42M | -8.04M | 32.74M | 2.18B | -45.05M | 650.05M | -131.27M | -145.22M | -280.45M | -47.15M | 1.37B | -131.65M | 584.91M | -465.13M | 127.80M | 846.82M | -52.40M |
| Capital Expenditure | -11.01M | -12.53M | -14.79M | -83.59M | -71.48M | -84.46M | -69.88M | -63.25M | -68.77M | -69.65M | -125.40M | -114.78M | -104.24M | -105.45M | -122.22M | -180.71M | -197.38M |
| Free Cash Flow | 27.70M | 49.44M | 42.37M | 90.43M | 290.69M | 301.30M | 233.94M | 183.72M | 150.00M | 156.72M | 5.55M | 187.15M | 251.86M | -161.31M | 12.77M | -67.21M | 19.92M |
| Share Buybacks | - | - | - | - | 0 | 0 | 27.37M | 20.81M | 0 | 200.00M | 0 | 0 | - | 0 | 0 | 4.77M | 3.50M |
| Dividends Paid | - | 205.00K | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 35.4% | 35.3% | 34.6% | 29.4% | 31.0% | 32.0% | 31.2% | 31.2% | 34.7% | 33.3% | 42.1% | 53.9% | 54.5% | 55.6% | 58.0% | 56.0% | 59.8% |
| Operating Margin % | 7.5% | 6.3% | 3.7% | 3.6% | 9.7% | 8.9% | 7.7% | 7.4% | 7.0% | 6.9% | 6.1% | -5.9% | -4.4% | -4.6% | -3.8% | -36.8% | -50.0% |
| Net Margin % | 4.5% | 3.0% | 0.7% | -1.6% | 4.2% | 8.5% | 4.9% | 4.0% | 7.8% | 6.4% | -15.9% | 3.8% | 5.0% | -0.9% | -1.9% | -39.2% | -52.7% |
| ROE % | 11.0% | 7.5% | 2.4% | -3.4% | 7.1% | 12.5% | 5.5% | 4.4% | 4.3% | 4.3% | -15.3% | 1.2% | 1.6% | -0.4% | -1.0% | -32.2% | -79.5% |
| ROCE % | - | 4.1% | 3.1% | 2.8% | 7.8% | 6.9% | 4.7% | 4.5% | 2.4% | 2.8% | 3.1% | -1.0% | -0.8% | -1.9% | -1.6% | -18.5% | -34.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 17.85% | 10.30M | $182.13M |
| 2 | American Century Companies Inc | 10.59% | 6.11M | $108.03M |
| 3 | Vanguard Portfolio Management LLC | 6.81% | 3.93M | $69.46M |
| 4 | Rubric Capital Management LP | 6.76% | 3.90M | $68.99M |
| 5 | Vanguard Capital Management LLC | 4.31% | 2.48M | $43.95M |
| 6 | State Street Corporation | 4.27% | 2.46M | $43.57M |
| 7 | Davenport & Co LLC | 4.06% | 2.34M | $41.42M |
| 8 | Hood River Capital Management LLC | 3.99% | 2.30M | $40.68M |
| 9 | FMR, LLC | 3.83% | 2.21M | $39.07M |
| 10 | Goldman Sachs Group Inc | 3.07% | 1.77M | $31.36M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ENOV
Enovis Corporation (ENOV) Stock forecasts - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNR3ItVlJaX3NEU2FWOHVLR1RaVGNCaXQ1VS12b3g4UXZXVEZTanFEc1hoR1Jrd3Y3M3NxNlRrRE5OZm10QzNYSEt4QVp0Nm04QVBvY0Qyc1RHT0dCOUlORWxDZVpEOGxMdXdkUjNONURVT0Joa3VjNGcwbEExT2E1M1ZDNlp2aUhJcHg0aF…
Enovis Corporation Estimates – NYSE:ENOV - TradingView
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTFBqb3VpZ0R5anVhZEJOTUNKSEc3cUZlYmE2bzUxQXhXb091VkIzS21IOVpvWXp1cnhVQ0R5TDRXaHlLYTB2N2JPLVFXWGRPVmx3d1FieFNGT3J2dkZ4T2RRN2owS0Z1RTZZcVZTbzZNYVhpdEh2Q1E?oc=5" target="_blank">Enovis C…
Enovis Corporation (ENOV) Stock Forecasts - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxNSWx0NVkzb1IyTjhSTnZ4UjNKMXc4YTZtNHYybkFLWjNDY3JwbTZJMGgxYUZmYWhRS0hYbnNpQjNMNHNEcld2bVd3ZWZidzFRNWhOZUZKaVN6Ul9LVDVPcU1jSDdGeHRvYXFCZzRXbWg3WEdIZ2JuY1N6RDc0Ml9VNV9OTHBzT3NKQlVGY2…
Is Enovis (ENOV) Stock Cheap After Reaffirming 2026 Guidance? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPQzdrcmtjRF9EU1ZKYVpOLWpra29kV0RZc2JtcnMtQ2toM3FsQnpnWTdtWnBSRmJWM01obHN4Q1FVVjRPNVk4OE9NaE96VGxhTmlnLWJUcDBQS1RBMl9XckVad1NyQ0xxYmU2YUU4Tlh1bnNFLVNMWVJEM0NzYXQ3WU4zRGQ3X2p4cW5scG…
Enovis (ENOV) Stock Fair Value Falls As Analysts Weigh Robotics And Margin Pressure - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQYjdWcnFsdER5dmJ5N3M0RldMaEM0VXFVbTBtUmR5YWhqNjZXS3NBM2VtMHpYTnk2cktsSVpSelF2UlRwb0Vjd0RxcVhfRXVhTFNYWFI1OEw2MW16SFVNZkNKLUY4MUt3T0ZwNVZWbzZmMmFPd3JveVdPT3ViRnVXWFlDbEUzN0lTWFZ3Wm…
ENOV Apr 2027 15.000 put (ENOV270416P00015000) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5RSjV2OFRqZXNDTEJoQVAyX1haSklSSmt1dm13UTdVMTA1emFzdm9raFpOR3Rxd1pMQWhtcXI0MG5HdE9GVzZWZ1pOYzVnQWV0NFhzZ1Z5Zkw3ZklKTzMtVktjRjRfQQ?oc=5" target="_blank">ENOV Apr 2027 15.000 put (ENO…
ENOV — Frequently Asked Questions
What is the current share price of Enovis Corporation (ENOV)?
As of 2026-10-23 16:27 PDT, Enovis Corporation (ENOV) trades at $21.08 on NYSE. Its 52-week range is $17.43 to $33.32.
What is the market capitalisation of ENOV?
Enovis Corporation (ENOV) has a market capitalisation of $1.22B on NYSE.
What is the P/E ratio of ENOV?
ENOV trades at a trailing price-to-earnings (P/E) ratio of -1.10. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 0.69.
What is the return on equity (ROE) of ENOV?
ENOV has a return on equity (ROE) of -54.14%. Its return on capital employed (ROCE) is -34.74%.
Is ENOV a good stock to buy?
This page provides a data-driven analysis of Enovis Corporation (ENOV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.